Other

Debt Securities, Available-for-Sale, Amortized Cost, Including Cash Equivalents

Alnylam Pharmaceuticals Debt Securities, Available-for-Sale, Amortized Cost, Including Cash Equivalents increased by 26.0% to $1.60B in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2025
Last reportedQ1 2026
Metric ID: other_debt_securities_available_for_sale_amortized_cost__b4f4aa

Historical Data

2 periods
 Q4 '25Q1 '26
Value$1.27B$1.60B
QoQ Change—+26.0%
Range$1.27B – $1.60B

Frequently Asked Questions

What is Alnylam Pharmaceuticals's debt securities, available-for-sale, amortized cost, including cash equivalents?
Alnylam Pharmaceuticals (ALNY) reported debt securities, available-for-sale, amortized cost, including cash equivalents of $1.60B in Q1 2026.